Jeffrey Cummings1,2. 1. Department of Brain Health, School of integrated Health Sciences, UNLV, Las Vegas, NV, USA. 2. Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA.
Abstract
REASONS FOR THE STUDY: The Neuropsychiatric Inventory (NPI) has been used for studies of neuropsychiatric symptoms in neurodegenerative disorders for the past 25 years. This article reviews the history of the development and application of the NPI. MAIN FINDINGS: The NPI consists of 10 (or 12) items that are assayed with questions, subquestions, and ratings of frequency and severity. The NPI has been shown to be valid and reliable. The NPI has been translated into approximately 40 languages; it has 4 of versions designed for different clinical applications. The NPI studies show contrasting profiles of behavioral symptoms in different neurologic disorders. The NPI has been used in approximately 350 clinical trials. In economic studies, the NPI captures the cost of behavioral symptoms in dementias. PRINCIPLE CONCLUSIONS: The NPI is a useful instrument for capturing behavioral changes in Alzheimer disease and other neurodegenerative disorders.
REASONS FOR THE STUDY: The Neuropsychiatric Inventory (NPI) has been used for studies of neuropsychiatric symptoms in neurodegenerative disorders for the past 25 years. This article reviews the history of the development and application of the NPI. MAIN FINDINGS: The NPI consists of 10 (or 12) items that are assayed with questions, subquestions, and ratings of frequency and severity. The NPI has been shown to be valid and reliable. The NPI has been translated into approximately 40 languages; it has 4 of versions designed for different clinical applications. The NPI studies show contrasting profiles of behavioral symptoms in different neurologic disorders. The NPI has been used in approximately 350 clinical trials. In economic studies, the NPI captures the cost of behavioral symptoms in dementias. PRINCIPLE CONCLUSIONS: The NPI is a useful instrument for capturing behavioral changes in Alzheimer disease and other neurodegenerative disorders.
Authors: Gary E Gibson; José A Luchsinger; Rosanna Cirio; Huanlian Chen; Jessica Franchino-Elder; Joseph A Hirsch; Lucien Bettendorff; Zhengming Chen; Sarah A Flowers; Linda M Gerber; Thomas Grandville; Nicole Schupf; Hui Xu; Yaakov Stern; Christian Habeck; Barry Jordan; Pasquale Fonzetti Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Katherine P Rankin; Gianina Toller; Lauren Gavron; Renaud La Joie; Teresa Wu; Tal Shany-Ur; Patrick Callahan; Maggie Krassner; Joel H Kramer; Bruce L Miller Journal: Front Neurol Date: 2021-09-07 Impact factor: 4.086
Authors: Ibrahim Almubark; Lin-Ching Chang; Kyle F Shattuck; Thanh Nguyen; Raymond Scott Turner; Xiong Jiang Journal: Front Aging Neurosci Date: 2020-12-03 Impact factor: 5.750
Authors: Marie H Gedde; Bettina S Husebo; Ipsit V Vahia; Janne Mannseth; Maarja Vislapuu; Mala Naik; Line I Berge Journal: BMJ Open Date: 2022-01-24 Impact factor: 2.692
Authors: L M Chahine; R Feldman; A Althouse; B Torsney; L Alzyoud; S Mantri; B Edison; S Albert; M Daeschler; C Kopil; C Marras Journal: J Neurol Date: 2021-02-25 Impact factor: 4.849